Cadrenal Therapeutics, Inc. - CVKD STOCK NEWS

Cadrenal Therapeutics, trading under the ticker CVKD, will present at the Emerging Growth Conference on June 12, 2024. The company's management will deliver a webcasted presentation at 10:50 am ET, focusing on their lead product, tecarfarin, a new-generation Vitamin K Antagonist designed to prevent cardiovascular incidents. Attendees can join the live session or access an archived version later. Additionally, the company will hold one-on-one investor meetings post-conference. For meeting requests, attendees can contact the Emerging Growth Conference representative or email Cadrenal's investor relations team.

Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. Tecarfarin has received Orphan Drug Designation from the FDA for preventing thromboembolism in patients with mechanical circulatory support devices like LVADs.

The ARIES-HM3 data indicates a direct correlation between lower therapeutic range times (TTR) and higher bleeding events. The average patient experienced a 30% rate of serious bleeding even without aspirin in the regimen. Incremental improvements in TTR corresponded to significant reductions in bleeding rates, emphasizing the potential of tecarfarin to provide more stable anticoagulation compared to warfarin.

The data is under FDA review, and Cadrenal plans to pursue further pivotal trials to validate tecarfarin's effectiveness for LVAD patients.

Cadrenal Therapeutics, a biopharmaceutical company, will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, trading under the Nasdaq symbol CVKD, is developing tecarfarin, an advanced oral anticoagulant aimed at preventing heart attacks, strokes, and deaths from blood clots in patients with rare cardiovascular conditions. A webcasted presentation is scheduled for 12:30pm ET on May 30, 2024, accessible via the conference homepage or directly through a provided link. The presentation will be available for replay. Additionally, the company’s management will host virtual one-on-one meetings with investors throughout the event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.

Cadrenal Therapeutics, Inc. provided a corporate update for Q1 2024, highlighting receiving FDA Orphan Drug Designation for tecarfarin to prevent thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices. The company appointed a new COO, engaged in strategic partnerships, and emphasized the need for improved anticoagulant therapy. Q1 2024 operating expenses were $1.6 million with $6.6 million in cash balances as of March 31, 2024.

Cadrenal Therapeutics, Inc. (CVKD) to present tecarfarin, a novel anticoagulant, at Noble Capital Markets' Virtual Healthcare Equity Conference. The presentation includes a Q&A session and 1x1 meetings for investors. The webcast will be available on the company's website and Channelchek for 90 days.

Cadrenal Therapeutics, Inc. (CVKD) receives FDA Orphan Drug Designation for tecarfarin, a novel anticoagulant for rare cardiovascular conditions, expanding treatment options and market exclusivity.

Cadrenal Therapeutics, Inc. (CVKD) provided a corporate update, expanding tecarfarin development to include new medical conditions, engaged in strategic partnerships, appointed a new COO, and reported Q4 2023 financials. Recent reports show positive equity research coverage and participation in key conferences.

Cadrenal Therapeutics, Inc. (CVKD) announces participation at THT 2024 to discuss tecarfarin, a novel oral anticoagulant for rare medical conditions. Tecarfarin aims to prevent heart attacks, strokes, and deaths due to blood clots. It has FDA designations for ESKD, AFib, and APS. Tecarfarin offers a different metabolism pathway than warfarin and has shown positive results in human trials.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has appointed Jeff Cole as the Chief Operating Officer to oversee manufacturing, supply chain operations, intellectual property, commercialization strategies, and partnering activities for tecarfarin, a novel Vitamin K Antagonist for anticoagulation therapy. With over 25 years of experience in global pharmaceutical manufacturing and commercial operations, Mr. Cole's appointment is expected to support the company's tecarfarin clinical program and evaluate partnering opportunities. His previous roles at Valeant Pharmaceuticals International and Espero BioPharma demonstrate a strong track record in product development, supply, and commercial operations. The appointment reflects the company's focus on addressing unmet needs for patients with left ventricular assist devices (LVADs), antiphospholipid syndrome (APS), end-stage kidney disease (ESKD), and atrial fibrillation (AFib).